Attention Deficit and Hyperkinetic Disorders Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 59 studies associated with Attention Deficit and Hyperkinetic Disorders.
Here is a small sampling of Attention Deficit and Hyperkinetic Disorders studies by title:
- The prevalence of cannabis use disorder in attention-deficit hyperactivity disorder: A clinical epidemiological meta-analysis
- Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review
- Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
- Differences in alcohol and cannabis use amongst substance use disorder patients with and without comorbid attention-deficit/hyperactivity disorder
- Attention deficit hyperactivity disorder symptoms and cannabis use after one year among students of the i-Share cohort
Components of the Attention Deficit and Hyperkinetic Disorders Research Dashboard
- Dosing information available for Attention Deficit and Hyperkinetic Disorders
- Chemotype guidance for treating Attention Deficit and Hyperkinetic Disorders with cannabis
- Synopsis of cannabis research for Attention Deficit and Hyperkinetic Disorders
- Individual study details for Attention Deficit and Hyperkinetic Disorders
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Attention Deficit and Hyperkinetic Disorders
Description of Attention Deficit and Hyperkinetic Disorders
Orthodox medicine is unsure of what causes ADHD, nor does it provide a cure.
The current hypothesis suggests a combination of factors, including nutrition (or the lack of it), junk food (i.e., incredibly refined or artificial sugars, artificial taste enhancers such as glutamate), environmental toxins (i.e., lead, smoking, electro-pollution, organophosphate insecticides), epigenetics, genetic (i.e., genes involved in dopamine production or use), or specific social conditions (i.e., forms of PTSD).
The disorder is primarily managed with mind-altering psychoactive drugs to increase dopamine and norepinephrine neurotransmitters. The increase is achieved by given drugs such as Adderall or Desoxyn (amphetamines-based salts), Strattera (norepinephrine reuptake inhibitor), or Ritalin (dopamine and norepinephrine reuptake inhibitors)—medicines which are basically and as such (especially Desoxyn which is methamphetamine) carry with them a high-risk drug for abuse and addiction.
Drugs are delivered orally as pills, skin patches, or liquid.
Adverse effects of psycho-stimulants may include a lack of appetite, insomnia, tics, feeling 'high' or 'funny,' psychotic episodes (hearing voices, hallucination, paranoia), or cardiovascular problems.
Disease Classification
Condition: ADD and ADHDDisease Family: Mental Disorders
Organ System: Mental/Emotional System, Nervous System
ICD-10 Chapter: Mental and Behavioural Disorders
ICD-10 Code: F90
Attention Deficit and Hyperkinetic Disorders Symptoms:
Difficulty concentrating, hyperactivity, restlessness, poor impulse control, impatience, disruptive behaviorAlso known as:
ADD, ADHD, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Attention deficit hyperactivity disorder combined, Adhd combined type, Attention-deficit hyperactivity disorder predominantly hyperactive type, Attention-deficit hyperactivity disorder predominantly inattentive typeDrug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
